Call to Find Out if You Qualify: 800-718-1021 Understanding Clinical Trials
About the Study Drug
Tasocitinib (CP-690,550) is being developed as a potential disease-modifying anti-rheumatic drug delivered orally in pill form.
Am I a Trial Candidate?
If you suffer from RA, you may be eligible to participate in the ORAL trials.
Call 800-718-1021.
Tell a Friend
Do you know someone with RA? Patients are being recruited now for the ORAL trials.
